National Instruments reports record quarterly revenue in Q3

OCTOBER 29, 2007--National Instruments (Austin, TX, USA) has reported record quarterly revenue of $184.4 million in the third quarter, ended Sept. 30, 2007.

OCTOBER 29, 2007--National Instruments (NI; Austin, TX, USA; www.ni.com) has reported record quarterly revenue of $184.4 million in the third quarter, ended Sept. 30, 2007, up 12.4% as compared to Q3 2006. Diluted earnings per share (EPS) for Q3 2007 were $0.27. This is above the midpoint of NI guidance of $0.24 to $0.29 per share. Net income was $21.5 million, up 15% from Q3 2006. For Q3 2007, operating margin and net margin were 13.3% and 11.7%, respectively.

"The release of LabVIEW 8.5 in Q3 marked another major milestone in our vision of graphical system design. The inherent parallelism of LabVIEW 8.5 makes it uniquely positioned to leverage multicore processors with little to no change in the way users develop their code," said James Truchard, NI president and CEO. "I believe our graphical system design approach for test, industrial, and embedded applications has defined a unique and defensible position for National Instruments."

NI virtual instrumentation and graphical system design products, which constitute the vast majority of the company's product portfolio, had 14.3% year-over-year revenue growth in Q3 2007. This represents another strong quarter of revenue growth from NI virtual instrument products. NI believes this continued strong growth validates the company's strategy of increased investment in R&D to drive new product success.

In contrast, sales of NI instrument control products which now represent less than 10% of our revenue were down 3% year-over-year in Q3, compared to an 8% decline in Q2 2007. The decline in the company's instrument control product sales was related to weakness of the Global PMI during the quarter.

"On reviewing Q3, we are particularly pleased that the success of our system-level platforms has enabled us to deliver record revenue and solid earnings growth despite a significant decline in the global PMI in Q3," said Alex Davern, NI CFO.


More in Life Sciences